Pancreatic Ductal Carcinoma clinical trials at UC Irvine
4 in progress, 3 open to eligible people
Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
open to eligible people ages 18 years and up
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
Orange, California and other locations
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
open to eligible people ages 18 years and up
This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).
Orange, California and other locations
RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
open to eligible people ages 18 years and up
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Orange, California and other locations
Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
Orange, California and other locations
Our lead scientists for Pancreatic Ductal Carcinoma research studies include Farshid Dayyani Zhaohui Arter Cathleen Park.
Last updated: